Hsp90 as a therapeutic target in endocrinology: current evidence

References

• Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem. 2009;78:959–991.
   PubMed Web of Science ®Google Scholar
• Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem. 2006;75:271–294.
   PubMed Web of Science ®Google Scholar
• Echeverria PC, Bernthaler A, Dupuis P, Mayer B, Picard D. An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine. PLoS One. 2011;6(10):e26044.
   PubMed Web of Science ®Google Scholar
• Taipale M, Jarosz DF, Lindquist S. Hsp90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol. 2010;11(7):515–528.
   PubMed Web of Science ®Google Scholar
• Taipale M, Krykbaeva I, Koeva M, et al. Quantitative analysis of Hsp90-client interactions reveals principles of substrate recognition. Cell. 2012;150(5):987–1001.
   Web of Science ®Google Scholar
• Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997;18(3):306–360.
   PubMed Web of Science ®Google Scholar
• Smith DF. Tetratricopeptide repeat cochaperones in steroid receptor complexes. Cell Stress Chaperones. 2004;9(2):109–121.
   Web of Science ®Google Scholar
• Picard D. Chaperoning steroid hormone action. Trends Endocrinol Metab. 2006;17(6):229–236.
   Web of Science ®Google Scholar
• Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003;228(2):111–133.
   PubMed Web of Science ®Google Scholar
• Ratajczak T, Ward BK, Minchin RF. Immunophilin chaperones in steroid receptor signalling. Curr Top Med Chem. 2003;3(12):1348–1357.
   Web of Science ®Google Scholar
• Smith DF, Toft DO. Minireview. The intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol. 2008;22(10):2229–2240.
   PubMedGoogle Scholar
• Röhl A, Rohrberg J, Buchner J. The chaperone Hsp90: changing partners for demanding clients. Trends Biochem Sci. 2013;38(5):253–262.
   PubMed Web of Science ®Google Scholar
• Kirschke E, Goswami D, Southworth D, Griffin PR, Agard DA. Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles. Cell. 2014;157(7):1685–1697.
   PubMed Web of Science ®Google Scholar
• Roe SM, Ali MM, Meyer P, et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(Cdc37). Cell. 2004;116(1):87–98.
   PubMed Web of Science ®Google Scholar
• Meyer P, Prodromou C, Hu B, et al. Structural and functional analysis of the middle segment of Hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell. 2003;11(3):647–658.
   PubMed Web of Science ®Google Scholar
• Li J, Richter K, Reinstein J, Buchner J. Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle. Nat Struct Mol Biol. 2013;20(3):326–331.
   PubMed Web of Science ®Google Scholar
• Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic Hsp90 complex in cancer. Nat Rev Cancer. 2010;10(8):537–549.
   PubMed Web of Science ®Google Scholar
• Moulick K, Ahn JH, Zong H, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol. 2011;7(11):818–826.
   Web of Science ®Google Scholar
• Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18(1):64–76.
   PubMed Web of Science ®Google Scholar
• Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012;1823(3):742–755.
   PubMed Web of Science ®Google Scholar
• Travers J, Sharp S, Workman P. Hsp90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discov Today. 2012;17(5–6):242–252.
   PubMed Web of Science ®Google Scholar
• Sreedhar AS, Kalmar E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004;562(1–3):11–15.
   PubMed Web of Science ®Google Scholar
• Kunisawa J, Shastri N. Hsp90α chaperones large C-terminally extended proteolytic intermediates in the MHC class I antigen processing pathway. Immunity. 2006;24(5):523–534.
   PubMed Web of Science ®Google Scholar
• Bouchier-Hayes L, Oberst A, McStay GP, et al. Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol Cell. 2009;35(6):830–840.
   Web of Science ®Google Scholar
• Ichiyanagi T, Imai T, Kajiwara C, et al. Essential role of endogenous heat shock protein 90 of dendritic cells in antigen cross-presentation. J Immunol. 2010;185(5):2693–2700.
   Web of Science ®Google Scholar
• Imai T, Kato Y, Kajiwara C, et al. Heat shock protein 90 (Hsp90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells. Proc Natl Acad Sci U S A. 2011;108(39):16363–16368.
   Web of Science ®Google Scholar
• Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for Hsp90α in cancer cell invasiveness. Nat Cell Biol. 2004;6(6):507–514.
   PubMed Web of Science ®Google Scholar
• Wang X, Song X, Zhuo W, et al. The regulatory mechanism of Hsp90α secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A. 2009;106(50):21288–21293.
   PubMed Web of Science ®Google Scholar
• Lei H, Romeo G, Kazlauskas A. Heat shock protein 90α-dependent translocation of annexin II to the surface of endothelial cells modulates plasmin activity in the diabetic rat aorta. Circ Res. 2004;94(7):902–909.
   Web of Science ®Google Scholar
• Lei H, Venkatakrishnan A, Yu S, Kazlauskas A. Protein kinase A-dependent translocation of Hsp90 α impairs endothelial nitric-oxide synthase activity in high glucose and diabetes. J Biol Chem. 2007;282(13):9364–9371.
   PubMed Web of Science ®Google Scholar
• Cortes-González C, Barrera-Chimal J, Ibarra-Sanchez M, et al. Opposite effect of Hsp90α and Hsp90β on eNOS ability to produce nitric oxide or superoxide anion in human embryonic kidney cells. Cell Physiol Biochem. 2010;26(4–5):657–668.
   Google Scholar
• Metchat A, Akerfelt M, Bierkamp C, et al. Mammalian heat shock factor 1 is essential for oocyte meiosis and directly regulates Hsp90α expression. J Biol Chem. 2009;284(14):9521–9528.
   Web of Science ®Google Scholar
• Grad I, Cederroth CR, Walicki J, et al. The molecular chaperone Hsp90α is required for meiotic progression of spermatocytes beyond pachytene in the mouse. PLoS One. 2010;5(12):e15770.
   Web of Science ®Google Scholar
• Kajiwara C, Kondo S, Uda S, et al. Spermatogenesis arrest caused by conditional deletion of Hsp90α in adult mice. Biol Open. 2012;1(10):977–982.
   Web of Science ®Google Scholar
• Voss AK, Thomas T, Gruss P. Mice lacking Hsp90β fail to develop a placental labyrinth. Development. 2000;127(1):1–11.
   PubMed Web of Science ®Google Scholar
• Millson SH, Truman AW, Racz A, et al. Expressed as the sole Hsp90 of yeast, the α and β isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90β generates sensitivity to the Hsp90 inhibitor radicicol. FEBS J. 2007;274(17):4453–4463.
   Web of Science ®Google Scholar
• Chadli A, Graham JD, Abel MG, et al. GCUNC45 is a novel regulator for the progesterone receptor/Hsp90 chaperoning pathway. Mol Cell Biol. 2006;26(5):1722–1730.
   PubMed Web of Science ®Google Scholar
• Chadli A, Felts SJ, Toft DO. GCUNC45 is the first Hsp90 co-chaperone to show α/β isoform specificity. J Biol Chem. 2008;283(15):9509–9512.
   Web of Science ®Google Scholar
• Correia AL, Mori H, Chen EI, Schmitt FC, Bissell MJ. The hemopexin domain of MMP3 is responsible for mammary epithelial invasion and morphogenesis through extracellular interaction with Hsp90β. Genes Dev. 2013;27(7):805–817.
   Web of Science ®Google Scholar
• Sternlicht MD, Lochter A, Sympson CJ, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 1999;98(2):137–146.
   PubMed Web of Science ®Google Scholar
• Pires ES, Khole VV. A block in the road to fertility: autoantibodies to heat-shock protein 90-β in human ovarian autoimmunity. Fertil Steril. 2009;92(4):1395–1409.
   Web of Science ®Google Scholar
• Choudhury A, Khole VV. Hsp90 antibodies: a detrimental factor responsible for ovarian dysfunction. Am J Reprod Immunol. 2013;70(5):372–385.
   Web of Science ®Google Scholar
• Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO. The Hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem. 2000;275(5):3305–3312.
   PubMed Web of Science ®Google Scholar
• Leskovar A, Wegele H, Werbeck ND, Buchner J, Reinstein J. The ATPase cycle of the mitochondrial Hsp90 analog Trap1. J Biol Chem. 2008;283(17):11677–11688.
   PubMed Web of Science ®Google Scholar
• Lavery LA, Partridge JR, Ramelot TA, Elnatan D, Kennedy MA, Agard DA. Structural asymmetry in the closed state of mitochondrial Hsp90 (TRAP1) supports a two-step ATP hydrolysis mechanism. Mol Cell. 2014;53(2):330–343.
   PubMed Web of Science ®Google Scholar
• Rasola A, Neckers L, Picard D. Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells. Trends Cell Biol. 2014;24(8):455–463.
   PubMed Web of Science ®Google Scholar
• Cechetto JD, Gupta RS. Immunoelectron microscopy provides evidence that tumor necrosis factor receptor-associated protein 1 (TRAP-1) is a mitochondrial protein which also localizes at specific extramitochondrial sites. Exp Cell Res. 2000;260(1):30–39.
   PubMed Web of Science ®Google Scholar
• Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, DC. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell. 2007;131(2):257–270.
   PubMed Web of Science ®Google Scholar
• Altieri DC, Stein GS, Lian JB, Languino LR. TRAP-1, the mitochondrial Hsp90. Biochim Biophys Acta. 2012;1823(3):767–773.
   PubMed Web of Science ®Google Scholar
• Pridgeon JW, Olzmann JA, Chin LS, Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 2007;5(7):e172.
   PubMed Web of Science ®Google Scholar
• Landriscina M, Laudiero G, Maddalena F, et al. Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents. Cancer Res. 2010;70(16):6577–6586.
   PubMed Web of Science ®Google Scholar
• Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012;31(14):3038–3062.
   PubMed Web of Science ®Google Scholar
• Corti O, Brice A. Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson’s disease. Curr Opin Neurobiol. 2013;23(1):100–108.
   Web of Science ®Google Scholar
• Saisawat P, Kohl S, Hilger AC, et al. Whole-exome resequencing reveals recessive mutations in TRAP1 in individuals with CAKUT and VACTERL association. Kidney Int. 2014;85(6):1310–1317.
   Web of Science ®Google Scholar
• Eletto D, Dersh D, Argon Y. GRP94 in ER quality control and stress responses. Semin Cell Dev Biol. 2010;21(5):479–485.
   PubMed Web of Science ®Google Scholar
• Marzec M, Eletto D, Argon Y. GRP94: An Hsp90-like protein specialized for protein folding and quality control in the endoplasmic reticulum. Biochim Biophys Acta. 2012;1823(3):774–787.
   PubMed Web of Science ®Google Scholar
• Lee AS. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer. 2014;14(4):263–276.
   PubMed Web of Science ®Google Scholar
• Krukenberg KA, Bottcher UM, Southworth DR, Agard DA. Grp94, the endoplasmic reticulum Hsp90, has a similar solution conformation to cytosolic Hsp90 in the absence of nucleotide. Protein Sci. 2009;18(9):1815–1827.
   Web of Science ®Google Scholar
• Dollins DE, Warren JJ, Immormino RM, Gewirth DT. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the Hsp90 chaperones. Mol Cell. 2007;28(1):41–56.
   Web of Science ®Google Scholar
• Lee AS. Mammalian stress response: induction of the glucose-regulated protein family. Curr Opin Cell Biol. 1992;4(2):267–273.
   PubMedGoogle Scholar
• Mori K. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell. 2000;101(5):451–454.
   PubMed Web of Science ®Google Scholar
• Ostrovsky O, Makarewich CA, Snapp EL, Argon Y. An essential role for ATP binding and hydrolysis in the chaperone activity of GRP94 in cells. Proc Natl Acad Sci U S A. 2009;106(28):11600–11605.
   Web of Science ®Google Scholar
• Weekes MP, Antrobus R, Talbot S, et al. Proteomic plasma membrane profiling reveals an essential role for gp96 in the cell surface expression of LDLR family members, including the LDL receptor and LRP6. J Proteome Res. 2012;11(3):1475–1484.
   PubMed Web of Science ®Google Scholar
• Ostrovsky O, Ahmed NT, Argon Y. The chaperone activity of GRP94 toward insulin-like growth factor II is necessary for the stress response to serum deprivation. Mol Biol Cell. 2009;20(6):1855–1864.
   Web of Science ®Google Scholar
• Christianson JC, Shaler TA, Tyler RE, Kopito RR. OS-9 and GRP94 deliver mutant α1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD. Nat Cell Biol. 2008;10(3):272–282.
   PubMed Web of Science ®Google Scholar
• Satoh T, Chen Y, Hu D, Hanashima S, Yamamoto K, Yamaguchi Y. Structural basis for oligosaccharide recognition of misfolded glycoproteins by OS-9 in ER-associated degradation. Mol Cell. 2010;40(6):905–916.
   Web of Science ®Google Scholar
• Seidler PM, Shinsky SA, Hong F, Li Z, Cosgrove MS, Gewirth DT. Characterization of the Grp94/OS-9 chaperone-lectin complex. J Mol Biol. 2014;426(21):3590–3605.
   Web of Science ®Google Scholar
• Mao C, Wang M, Luo B, et al. Targeted mutation of the mouse GRP94 gene disrupts development and perturbs endoplasmic reticulum stress signaling. PLoS One. 2010;5(5):e10852.
   PubMed Web of Science ®Google Scholar
• Liu B, Staron M, Hong F, et al. Essential roles of GRP94 in gut homeostasis via chaperoning canonical Wnt pathway. Proc Natl Acad Sci U S A. 2013;110(17):6877–6882.
   Web of Science ®Google Scholar
• Hua Y, White-Gilbertson S, Kellner J, et al. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma. Clin Cancer Res. 2013;19(22):6242–6251.
   Web of Science ®Google Scholar
• Morales C, Rachidi S, Hong F, et al. Immune chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis. Cancer Res. 2014;74(2):446–459.
   Web of Science ®Google Scholar
• Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425(6956):407–410.
   PubMed Web of Science ®Google Scholar
• Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med. 2004;10(6):283–290.
   Web of Science ®Google Scholar
• Taldone T, Ochiana SO, Patel PD, Chiosis G. Selective targeting of the stress chaperome as a therapeutic strategy. Trends Pharmacol Sci. 2014;35(11):592–603.
   PubMed Web of Science ®Google Scholar
• Beebe K, Mollapour M, Scroggins B, et al. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. Oncotarget. 2013;4(7):1065–1074.
   PubMedGoogle Scholar
• Patel HJ, Modi S, Chiosis G, Taldone T. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin Drug Discov. 2011;6(5):559–587.
   PubMed Web of Science ®Google Scholar
• Menezes DL, Taverna P, Jensen MR, et al. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol Cancer Ther. 2012;11(3):730–739.
   PubMed Web of Science ®Google Scholar
• Jego G, Hazoume A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett. 2013;332(2):275–285.
   PubMed Web of Science ®Google Scholar
• Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst. 2000;92(3):242–248.
   PubMed Web of Science ®Google Scholar
• Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today. 2004;9(20):881–888.
   PubMed Web of Science ®Google Scholar
• Chiosis G. Targeting chaperones in transformed systems – a focus on Hsp90 and cancer. Expert Opin Ther Targets. 2006;10(1):37–50.
   PubMed Web of Science ®Google Scholar
• Matts RL, Dixit A, Peterson LB, et al. Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol. 2011;6(8):800–807.
   PubMed Web of Science ®Google Scholar
• Matthews SB, Vielhauer GA, Manthe CA, et al. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate. 2010;70(1):27–36.
   Web of Science ®Google Scholar
• Kusuma BR, Peterson LB, Zhao H, Vielhauer G, Holzbeierlein J, Blagg BS. Targeting the heat shock protein 90 dimer with dimeric inhibitors. J Med Chem. 2011;54(18):6234–6253.
   Web of Science ®Google Scholar
• Allan RK, Mok D, Ward BK, Ratajczak T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J Biol Chem. 2006;281(11):7161–7171.
   PubMed Web of Science ®Google Scholar
• Chu [webpage on the Internet]. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem. 1994;269(2):787–790.
   PubMed Web of Science ®Google Scholar
• Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol. 2001;59(4):657–663.
   PubMed Web of Science ®Google Scholar
• Itoh H, Ogura M, Komatsuda A, Wakui H, Miura AB, Tashima Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone Hsp90. Biochem J. 1999;343(Pt 3):697–703.
   Google Scholar
• Rosenhagen MC, Soti C, Schmidt U, et al. The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol Endocrinol. 2003;17(10):1991–2001.
   Google Scholar
• Nardai G, Sass B, Eber J, Orosz G, Csermely P. Reactive cysteines of the 90-kDa heat shock protein, Hsp90. Arch Biochem Biophys. 2000;384(1):59–67.
   Web of Science ®Google Scholar
• Ngassapa O, Soejarto DD, Pezzuto JM, Farnsworth NR. Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea. J Nat Prod. 1994;57(1):1–8.
   Web of Science ®Google Scholar
• Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction. J Biol Chem. 2009;284(51):35381–35389.
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929–1935.
   PubMed Web of Science ®Google Scholar
• Tash JS, Chakrasali R, Jakkaraj SR, et al. Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90β) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cells. Biol Reprod. 2008;78(6):1139–1152.
   PubMed Web of Science ®Google Scholar
• Matts RL, Brandt GE, Lu Y, et al. A systematic protocol for the characterization of Hsp90 modulators. Bioorg Med Chem. 2011;19(1):684–692.
   Web of Science ®Google Scholar
• Ardi VC, Alexander LD, Johnson VA, McAlpine SR. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins. ACS Chem Biol. 2011;6(12):1357–1366.
   PubMed Web of Science ®Google Scholar
• McConnell JR, Alexander LA, McAlpine SR. A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. Bioorg Med Chem Lett. 2014;24(2):661–666.
   PubMed Web of Science ®Google Scholar
• Wandinger SK, Suhre MH, Wegele H, Buchner J. The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J. 2006;25(2):367–376.
   Web of Science ®Google Scholar
• Mollapour M, Tsutsumi S, Donnelly AC, et al. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell. 2010;37(3):333–343.
   PubMed Web of Science ®Google Scholar
• Mollapour M, Tsutsumi S, Kim YS, Trepel J, Neckers L. Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity. Oncotarget. 2011;2(5):407–417.
   Google Scholar
• Wang X, Lu XA, Song X, et al. Thr90 phosphorylation of Hsp90α by protein kinase A regulates its chaperone machinery. Biochem J. 2012;441(1):387–397.
   Google Scholar
• Mollapour M, Neckers L. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta. 2012;1823(3):648–655.
   PubMed Web of Science ®Google Scholar
• Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002;94(7):504–513.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Ren Y, Mohapatra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-α levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res. 2007;13(16):4882–4890.
   Web of Science ®Google Scholar
• Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18(5):601–607.
   PubMed Web of Science ®Google Scholar
• Kekatpure VD, Dannenberg AJ, Subbaramaiah K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem. 2009;284(12):7436–7445.
   PubMed Web of Science ®Google Scholar
• Plescia J, Salz W, Xia F, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 2005;7(5):457–468.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3(1):46–54.
   PubMed Web of Science ®Google Scholar
• Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A. 2003;100(24):13791–13796.
   PubMed Web of Science ®Google Scholar
• Horibe T, Kohno M, Haramoto M, Ohara K, Kawakami K. Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent. J Transl Med. 2011;9:8.
   PubMed Web of Science ®Google Scholar
• Zhao R, Leung E, Gruner S, Schapira M, Houry WA. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010;5(4):e9934.
   Google Scholar
• Zierer BK, Weiwad M, Rubbelke M, et al. Artificial accelerators of the molecular chaperone Hsp90 facilitate rate-limiting conformational transitions. Angew Chem Int Ed Engl. 2014;53(45):12257–12262.
   Web of Science ®Google Scholar
• Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone Aha1. Mol Cell. 2002;10(6):1307–1318.
   PubMed Web of Science ®Google Scholar
• Taldone T, Patel PD, Patel M, et al. Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. J Med Chem. 2013;56(17):6803–6818.
   PubMed Web of Science ®Google Scholar
• Ernst JT, Liu M, Zuccola H, et al. Correlation between chemotype-dependent binding conformations of Hsp90α/β and isoform selectivity-implications for the structure-based design of Hsp90α/β selective inhibitors for treating neurodegenerative diseases. Bioorg Med Chem Lett. 2014;24(1):204–208.
   PubMed Web of Science ®Google Scholar
• Ernst JT, Neubert T, Liu M, et al. Identification of novel Hsp90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington’s disease. J Med Chem. 2014;57(8):3382–3400.
   PubMed Web of Science ®Google Scholar
• Patel PD, Yan P, Seidler PM, et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol. 2013;9(11):677–684.
   PubMed Web of Science ®Google Scholar
• Soldano KL, Jivan A, Nicchitta CV, Gewirth DT. Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation. J Biol Chem. 2003;278(48):48330–48338.
   PubMed Web of Science ®Google Scholar
• Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000;21(1):55–89.
   PubMed Web of Science ®Google Scholar
• Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol. 2007;275(1–2):43–61.
   PubMed Web of Science ®Google Scholar
• Chrousos GP, Kino T. Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. Ann N Y Acad Sci. 2009;1179:153–166.
   PubMed Web of Science ®Google Scholar
• Whitesell L, Cook P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol. 1996;10(6):705–712.
   Google Scholar
• Fliss AE, Benzeno S, Rao J, Caplan AJ. Control of estrogen receptor ligand binding by Hsp90. J Steroid Biochem Mol Biol. 2000;72(5):223–230.
   Web of Science ®Google Scholar
• Vanaja DK, Mitchell SH, Toft DO, Young CY. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones. 2002;7(1):55–64.
   PubMed Web of Science ®Google Scholar
• Beliakoff J, Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs. 2004;15(7):651–662.
   PubMed Web of Science ®Google Scholar
• Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther. 2004;3(8):1021–1030.
   PubMed Web of Science ®Google Scholar
• Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1652–1654.
   PubMed Web of Science ®Google Scholar
• Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC. Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010;53(1):3–17.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8(4):440–448.
   PubMed Web of Science ®Google Scholar
• Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing’s disease of the omentum”? Lancet. 1997;349(9060):1210–1213.
   PubMed Web of Science ®Google Scholar
• Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 2007;21(9):2185–2194.
   PubMed Web of Science ®Google Scholar
• Lehrke M, Lazar MA. The many faces of PPARγ. Cell. 2005;123(6):993–999.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem. 2008;77:289–312.
   PubMed Web of Science ®Google Scholar
• Christodoulides C, Vidal-Puig A. PPARs and adipocyte function. Mol Cell Endocrinol. 2010;318(1–2):61–68.
   Web of Science ®Google Scholar
• Nguyen MT, Csermely P, Soti C. Hsp90 chaperones PPARγ and regulates differentiation and survival of 3T3-L1 adipocytes. Cell Death Differ. 2013;20(12):1654–1663.
   PubMed Web of Science ®Google Scholar
• Desarzens S, Liao WH, Mammi C, Caprio M, Faresse N. Hsp90 blockers inhibit adipocyte differentiation and fat mass accumulation. PLoS One. 2014;9(4):e94127.
   Web of Science ®Google Scholar
• Dahia PL, Grossman AB. The molecular pathogenesis of corticotroph tumors. Endocr Rev. 1999;20(2):136–155.
   Web of Science ®Google Scholar
• Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet. 2006;367(9522):1605–1617.
   PubMed Web of Science ®Google Scholar
• Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol. 2011;7(5):279–289.
   PubMed Web of Science ®Google Scholar
• Paez-Pereda M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest. 2001;108(8):1123–1131.
   PubMed Web of Science ®Google Scholar
• Riebold M, Kozany C, Freiburger L, et al. A C-terminal Hsp90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med. 2015;21(3):276–280.
   PubMed Web of Science ®Google Scholar
• Zhao H, Brandt GE, Galam L, Matts RL, Blagg BS. Identification and initial SAR of silybin: an Hsp90 inhibitor. Bioorg Med Chem Lett. 2011;21(9):2659–2664.
   PubMed Web of Science ®Google Scholar
• Manié S, Santoro M, Fusco A, Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet. 2001;17(10):580–589.
   Web of Science ®Google Scholar
• Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology. 2004;145(12):5448–5451.
   Web of Science ®Google Scholar
• Santoro M, Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab. 2006;2(1):42–52.
   Google Scholar
• Vidal M, Wells S, Ryan A, Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 2005;65(9):3538–3541.
   PubMed Web of Science ®Google Scholar
• Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab. 2009;94(5):1493–1499.
   PubMed Web of Science ®Google Scholar
• Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767–772.
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ. Lenvatinib in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(19):1868.
   Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630.
   PubMed Web of Science ®Google Scholar
• Marsee DK, Venkateswaran A, Tao H, et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J Biol Chem. 2004;279(42):43990–43997.
   Web of Science ®Google Scholar
• Alfano L, Guida T, Provitera L, et al. RET is a heat shock protein 90 (Hsp90) client protein and is knocked down upon Hsp90 pharmacological block. J Clin Endocrinol Metab. 2010;95(7):3552–3557.
   Web of Science ®Google Scholar
• Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol. 2001;19(15):3562–3571.
   PubMed Web of Science ®Google Scholar
• Sukhdeo K, Mani M, Zhang Y, et al. Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A. 2007;104(18):7516–7521.
   PubMed Web of Science ®Google Scholar
• Ashihara E, Kawata E, Nakagawa Y, et al. β-Catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res. 2009;15(8):2731–2738.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Bona RD, Chiosis G, Li Z. The anti-myeloma activity of a novel purine scaffold Hsp90 inhibitor PU-H71 is via inhibition of both Hsp90a and Hsp90b1. J Hematol Oncol. 2010;3:40.
   PubMed Web of Science ®Google Scholar
• Ishii T, Seike T, Nakashima T, et al. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012;2(4):e68.
   Google Scholar
• Stuhmer T, Iskandarov K, Gao Z, et al. Preclinical activity of the novel orally bioavailable Hsp90 inhibitor NVP-HSP990 against multiple myeloma cells. Anticancer Res. 2012;32(2):453–462.
   Web of Science ®Google Scholar
• Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76(2):149–168.
   PubMed Web of Science ®Google Scholar
• Grantham JJ. Polycystic kidney disease: neoplasia in disguise. Am J Kidney Dis. 1990;15(2):110–116.
   PubMed Web of Science ®Google Scholar
• Seeger-Nukpezah T, Proia DA, Egleston BL, et al. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease. Proc Natl Acad Sci U S A. 2013;110(31):12786–12791.
   Web of Science ®Google Scholar
• Barluenga S, Wang C, Fontaine JG, et al. Divergent synthesis of a pochonin library targeting Hsp90 and in vivo efficacy of an identified inhibitor. Angew Chem Int Ed Engl. 2008;47(23):4432–4435.
   Web of Science ®Google Scholar
• Barluenga S, Fontaine JG, Wang C, et al. Inhibition of Hsp90 with pochoximes: SAR and structure-based insights. Chembiochem. 2009;10(17):2753–2759.
   Web of Science ®Google Scholar
• Tash JS, Attardi B, Hild SA, Chakrasali R, Jakkaraj SR, Georg GI. A novel potent indazole carboxylic acid derivative blocks spermatogenesis and is contraceptive in rats after a single oral dose. Biol Reprod. 2008;78(6):1127–1138.
   Web of Science ®Google Scholar
• Gomez-Monterrey I, Sala M, Musella S, Campiglia P. Heat shock protein 90 inhibitors as therapeutic agents. Recent Pat Anticancer Drug Discov. 2012;7(3):313–336.
   Web of Science ®Google Scholar
• De Mattos-Arruda L, Cortes J. Breast cancer and Hsp90 inhibitors: is there a role beyond the HER2-positive subtype? Breast. 2012;21(4):604–607.
   Web of Science ®Google Scholar
• Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009;106(20):8368–8373.
   PubMed Web of Science ®Google Scholar
• Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin MJ. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp90. Clin Cancer Res. 2011;17(16):5432–5442.
   Web of Science ®Google Scholar
• Wong C, Chen S. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance. Cancer Res. 2009;69(22):8670–8677.
   Web of Science ®Google Scholar
• Yehuda R, Flory JD, Bierer LM, et al. Lower methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of veterans with posttraumatic stress disorder. Biol Psychiatr. 2015;77(4):356–364.
   PubMed Web of Science ®Google Scholar
• Jochems J, Teegarden SL, Chen Y, et al. Enhancement of stress resilience through histone deacetylase 6-mediated regulation of glucocorticoid receptor chaperone dynamics. Biol Psychiatr. 2015;77(4):345–355.
   Web of Science ®Google Scholar